Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes

Heart

Volumn 102, Issue 19, 2016, Pages 1581-1587

  Anyanwagu, Uchenna ^a   Mamza, Jil ^a   Mehta, Rajnikant ^a   Donnelly, Richard ^a   Idris, Iskandar ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT GAIN; AGED; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FACTUAL DATABASE; GLUCOSE BLOOD LEVEL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR;

ADULT; AGED; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; OBESITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84971570017     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-309164     Document Type: Article

References (29)

1. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
2. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72.
3. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. The Lancet 2009;374:1677-86.
4. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9.
6. American Diabetes Association (ADA). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1): S5-20.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
8. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008-17.
9. Currie CJ, Poole CD, Evans M, et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013;98:668-77.
10. Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. Jama 2014;311:2288-96.
11. Colayco DC, Niu F, McCombs JS, et al. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 2011;34:77-83.
12. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of Cardiovascular Disease Events in Patients with Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011;34:90-5.
13. Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011;2011:215764.
14. Okerson T, Chilton RJ. The Cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 2012;30:e146-55.
15. Blak BT, Thompson M, Dattani H, et al. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251-5.
16. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401.
17. Mamza J, Mehta R, Idris I. Obesity independently predicts responders to biphasic insulin 50/50 (Humalog Mix50 and Insuman Comb 50) following conversion from other insulin regimens: a retrospective cohort study. BMJ Open Diabetes Res Care 2014;2:e000021.
18. Mamza J, Mehta R, Donnelly R, et al. Comparative efficacy of adding sitagliptin to metformin, sulfonylurea or dual therapy: a propensity score-weighted cohort study. Diabetes Ther 2015;6:213-26.
19. Paul SK, Klein K, Maggs D, et al. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol 2015;14:1-9.
20. Avogaro A, Vigili de Kreutzenberg S, Fadini GP. Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. Curr Diab Rep 2014;14:483.
21. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-9.
22. Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013;347:f4533.
23. Cho E, Manson JE, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease among diabetic women. Diabetes Care 2002;25: 1142-8.
24. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29: 2333-48.
25. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009;32:762-8.
26. D'Alessio D, Häring HU, Charbonnel B, et al. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab 2015;17:170-8.
27. Nauck M, Horton E, Andjelkovic M, et al. Taspoglutide, a once-weekly glucagon-like peptide1 analogue, vs. insulin glargine titrated to target in patients with Type2 diabetes: an open-label randomized trial. Diabet Med 2013;30: 109-13.
28. Aas AM, Öhrvik J, Malmberg K, et al. DIGAMI 2 Investigators. Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study. Diabetes Obes Metab 2009;11:323-9.
29. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007; 9: 799-812.